A top priority in pre-eclampsia research: development of a reliable and inexpensive urinary screening test

Marco Scioscia; Gustaaf A. Dekker; Gérard Chaouat; Lalita Dawonauth; Ralf Dechend; Debra Goldman-Wohl; Erry Gumilar; S. Ananth Karumanchi; Douglas B. Kell; Thomas W. Rademacher; Sarah Robertson; Shigeru Saito; Sicco Scherjon; Anne C. Staff; Manu Vatish; Pierre Yves Robillard

doi:10.1016/S2214-109X(19)30319-5

A top priority in pre-eclampsia research: development of a reliable and inexpensive urinary screening test

Marco Scioscia, Gustaaf A. Dekker, Gérard Chaouat, Lalita Dawonauth, Ralf Dechend, Debra Goldman-Wohl, Erry Gumilar, S. Ananth Karumanchi, Douglas B. Kell, Thomas W. Rademacher, Sarah Robertson, Shigeru Saito, Sicco Scherjon, Anne C. Staff, Manu Vatish, Pierre Yves Robillard

Research output: Contribution to journal › Comment/debate

8 Citations (Scopus)

Original language	English
Pages (from-to)	e1312-e1313
Journal	The Lancet Global Health
Volume	7
Issue number	10
DOIs	https://doi.org/10.1016/S2214-109X(19)30319-5
Publication status	Published - Oct 2019

Access to Document

10.1016/S2214-109X(19)30319-5

Cite this

Scioscia, M., Dekker, G. A., Chaouat, G., Dawonauth, L., Dechend, R., Goldman-Wohl, D., Gumilar, E., Karumanchi, S. A., Kell, D. B., Rademacher, T. W., Robertson, S., Saito, S., Scherjon, S., Staff, A. C., Vatish, M., & Robillard, P. Y. (2019). A top priority in pre-eclampsia research: development of a reliable and inexpensive urinary screening test. The Lancet Global Health, 7(10), e1312-e1313. https://doi.org/10.1016/S2214-109X(19)30319-5

@article{a5320b857e2c4c838bb1726ed0d80329,

title = "A top priority in pre-eclampsia research: development of a reliable and inexpensive urinary screening test",

author = "Marco Scioscia and Dekker, {Gustaaf A.} and G{\'e}rard Chaouat and Lalita Dawonauth and Ralf Dechend and Debra Goldman-Wohl and Erry Gumilar and Karumanchi, {S. Ananth} and Kell, {Douglas B.} and Rademacher, {Thomas W.} and Sarah Robertson and Shigeru Saito and Sicco Scherjon and Staff, {Anne C.} and Manu Vatish and Robillard, {Pierre Yves}",

note = "Funding Information: TWR reports being a co-author on inositol phosphoglycans pre-eclampsia publications while on the University College London Medical School board. TWR was a coinventor on an InositolPhospho Glycan pre-eclampsia diagnostic patent, which has now lapsed. TWR provides laboratory reagents to academic groups for pre-eclampsia clinical trials. SAK reports consultancy work for Roche and Thermofisher and receiving a research grant from Siemens during the writing of this Comment; being a founder and advisory board member of Aggamin Pharmaceuticals outside the submitted work; Preeclampsia Biomarker patents with royalties paid to Beth Israel Deaconess Medical Center; and being a member of the Scientific Advisory Board for the Pre-eclampsia Foundation. All other authors declare no competing interests.",

year = "2019",

month = oct,

doi = "10.1016/S2214-109X(19)30319-5",

language = "English",

volume = "7",

pages = "e1312--e1313",

journal = "The Lancet Global Health",

issn = "2214-109X",

publisher = "Elsevier BV",

number = "10",

}

Scioscia, M, Dekker, GA, Chaouat, G, Dawonauth, L, Dechend, R, Goldman-Wohl, D, Gumilar, E, Karumanchi, SA, Kell, DB, Rademacher, TW, Robertson, S, Saito, S, Scherjon, S, Staff, AC, Vatish, M & Robillard, PY 2019, 'A top priority in pre-eclampsia research: development of a reliable and inexpensive urinary screening test', The Lancet Global Health, vol. 7, no. 10, pp. e1312-e1313. https://doi.org/10.1016/S2214-109X(19)30319-5

TY - JOUR

T1 - A top priority in pre-eclampsia research

T2 - development of a reliable and inexpensive urinary screening test

AU - Scioscia, Marco

AU - Dekker, Gustaaf A.

AU - Chaouat, Gérard

AU - Dawonauth, Lalita

AU - Dechend, Ralf

AU - Goldman-Wohl, Debra

AU - Gumilar, Erry

AU - Karumanchi, S. Ananth

AU - Kell, Douglas B.

AU - Rademacher, Thomas W.

AU - Robertson, Sarah

AU - Saito, Shigeru

AU - Scherjon, Sicco

AU - Staff, Anne C.

AU - Vatish, Manu

AU - Robillard, Pierre Yves

N1 - Funding Information: TWR reports being a co-author on inositol phosphoglycans pre-eclampsia publications while on the University College London Medical School board. TWR was a coinventor on an InositolPhospho Glycan pre-eclampsia diagnostic patent, which has now lapsed. TWR provides laboratory reagents to academic groups for pre-eclampsia clinical trials. SAK reports consultancy work for Roche and Thermofisher and receiving a research grant from Siemens during the writing of this Comment; being a founder and advisory board member of Aggamin Pharmaceuticals outside the submitted work; Preeclampsia Biomarker patents with royalties paid to Beth Israel Deaconess Medical Center; and being a member of the Scientific Advisory Board for the Pre-eclampsia Foundation. All other authors declare no competing interests.

PY - 2019/10

Y1 - 2019/10

UR - http://www.scopus.com/inward/record.url?scp=85072179496&partnerID=8YFLogxK

U2 - 10.1016/S2214-109X(19)30319-5

DO - 10.1016/S2214-109X(19)30319-5

M3 - Comment/debate

C2 - 31537353

AN - SCOPUS:85072179496

SN - 2214-109X

VL - 7

SP - e1312-e1313

JO - The Lancet Global Health

JF - The Lancet Global Health

IS - 10

ER -